Healthcare
Haemonetics Corporation(HAE)
Live Price
Offline$74.17
+1.98% today
1Y Change
+2.86%
Window
Jun 26, 2025 โ Jun 15, 2026
- Market Cap
- $2.79B
- Revenue Growth
- +4.0%
- EPS Growth
- +42.7%
- Dividend Yield
- 0.0%
Coverage: 243 bars ยท Jun 26, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Haemonetics Corporation (HAE) is a Healthcare stock with a market cap of $2.79B and listed on NYSE. The stock last traded around $74.17 and up 2.9% across the available one-year price window (Jun 26, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +4.0%, EPS growth of +42.7%, a dividend yield of 0.0%. What stands out right now is revenue +4.0%, EPS +42.7%, free cash flow +23.4% with operating margin 19.2% and ROIC 8.7%. Valuation is more restrained than many high-expectation growth names at P/E 16.0 and price/sales 2.1. Stock Foundry combines HAE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+4.0% vs +7.6% peer median
Operating Margin
Near sector median
+19.2% vs +19.4% peer median
P/E
Below sector median
16.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +4.0% and EPS at +42.7%, with operating margin around 19.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.3% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | +1.4% | +5.1% | +31.1% |
2026 Feb 5, 2026 | +3.1% | -8.7% | -11.4% | -1.4% |
2025 Nov 6, 2025 | +13.4% | +1.9% | +10.1% | +25.1% |
Benchmark Edge
HAE vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
HAE
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
HAE Max Drawdown
-40.06%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for HAE and SPY.
Company Overview
Haemonetics Corporation
New York Stock Exchange
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
- Leadership
- Christopher A. Simon
- IPO Date
- May 10, 1991
- Employees
- 3.7k
- Street Address
- 125 Summer Street
- Mailing
- Boston, MA, 02110
- Region
- Boston, MA, US
- Reporting Currency
- USD
- Investor Line
- 781 848 7100
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 16.0
- EV/EBITDA
- 9.7
- Price/Sales
- 2.1
- Price/Book
- 3.1
Growth
- Revenue
- +4.0%
- EPS
- +42.7%
- Free Cash Flow
- +23.4%
Profitability
- Gross Margin
- 58.5%
- Operating Margin
- 19.2%
- Net Margin
- 13.3%
- ROE
- 20.3%
- ROIC
- 8.7%
Balance Sheet
- Debt/Equity
- 1.34
- Current Ratio
- 1.75
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.